In the present study, the antispasmodic drug mebeverine hydrochloride and the antiulcer drug troxipide were tested for their possible antibacterial properties in vitro. The antimicrobial assays of the above drugs were determined with ampicillin, penicillin and ciprofloxacin against sensitive and resistant strains and their resistance were confirmed through Polymerase Chain Reaction by identifying the presence of the mecA gene. A computeraided method was used for screening the effectiveness of the drug interactions. Mebeverine and troxipide inhibited most of the sensitive and resistant strains tested in vitro from 32.5 to 125 µg/mL. The loss of structural alterations of the cell wall was analyzed by atomic force microscopy. In docking studies, troxipide and mebeverine were found to have substantial inhibition against penicillin binding protein 2a (IVQQ) and UDP-Nacetylglucosamine 1-carboxyvinyltransferase (2YVW) receptor proteins that seem to have interacted with most of the residues. This article was downloaded by you on: Sep 25, 2016 these assumed targets were involved in more than one metabolic pathways of MRSA.
Article Info
Materials and Methods
Bacterial strainsS. aureus NCIM 2079, K. pneumoniae NCIM 2719, and Enterobacter cloacae NCIM 2164 were obtained from NCIM, Pune. Clinical strain S. aureus, Escherichia coli and Enterococcus faecalis were obtained from KAP Viswanathan Medical College, Tiruchirappalli, Tamil Nadu, India. The strains were confirmed and stored at 4°C until use.
DrugsTroxipide, mebeverine hydrochloride, metaclopropamide and aceclofenac were obtained as pure drugs from Sigma Aldrich, India and kept under refrigeration until use.
MediaNutrient broth, Muller-Hinton broth, nutrient agar and Muller-Hinton agar were prepared and steam sterilized at 15 psi for 15 min by autoclaving.